Gynecologic Cancers | Topics

 
FDA Accepts for Review Supplemental Biologics License of Pembrolizumab for MSI-H/dMMR Advanced Endometrial Cancer
August 10, 2021

The phase 2 KEYNOTE-158 trial has demonstrated promising responses in patients with microsatellite instability–high/ mismatch repair deficient advanced endometrial carcinoma, and led to the FDA accepting a review of a new supplemental biologics license application for the drug.

Improving Social Needs For Women With Gynecological Cancer Could Improve Outcomes and Lessen Healthcare Disparities
August 04, 2021

Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.

ERBB2/ERBB3+ Uterine Cancer Shows Disease Control With Combination of Pertuzumab and Trastuzumab
June 07, 2021

Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers.

Cemiplimab Improves OS Versus Chemotherapy Across Histologic Subtypes in Recurrent Cervical Cancer
May 14, 2021

Results presented at part of the European Society for Medical Oncology Virtual Plenary show positive results of a phase 3 trial comparing cemiplimab with chemotherapy for previously treated cervical cancer.

Pembrolizumab Plus Lenvatinib Earns Priority Review in 2 Disease Indications
May 06, 2021

In the advanced treatment setting, an FDA decision has indicated that the combination of pembrolizumab and lenvatinib may soon be available for certain patients with endometrial tumors and renal cell carcinoma.

Thermal Ablation Presents Safe and Effective Alternative for Local Control of Metastatic Gynecologic Tumors
April 29, 2021

Data examining thermal ablation for women with a total of 119 metastatic gynecologic tumors found the therapy was safe and effective in the local control of these tumors.

Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies
April 12, 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.

Ronnie Shapira-Frommer, MD, on Next Steps for Exploring Pembrolizumab Monotherapy in Patients With Vulvar Squamous Cell Carcinoma
April 07, 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Characteristics of Responders With Vulvar Squamous Cell Carcinoma Treated on the KEYNOTE-158 Trial
April 05, 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were responders to pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Results From the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma
April 03, 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.